A retrospective analysis of 5-fluorouracil plus cisplatin as first-line chemotherapy in the recent treatment strategy for patients with metastatic or recurrent esophageal squamous cell carcinoma

被引：0
|
作者：
Shuji Hiramoto
Ken Kato
Hirokazu Shoji
Natsuko Okita
Atsuo Takashima
Yoshitaka Honma
Satoru Iwasa
Tetsuya Hamaguchi
Yasuhide Yamada
Yasuhiro Shimada
Narikazu Boku
机构：
[1] National Cancer Center Hospital,Gastrointestinal Medical Oncology Division
[2] Mitsubishi Kyoto Hospital,Department of Clinical Oncology and Palliative Medicine
来源：
International Journal of Clinical Oncology | 2018年 / 23卷
关键词：
Metastatic/recurrent esophageal cancer; First-line chemotherapy; 5-Fluorouracil + cisplatin; Prognostic factors;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：466 / 472
页数：6
相关论文
共 50 条
  • [41] The efficacy and safety of sintilimab combined with chemotherapy as the first-line treatment for metastatic esophageal squamous cell carcinoma
    Zhao, Zheng
    Yin, Ming-Mei
    Zhao, Wei-Feng
    Wang, Chao-Jie
    MEDICINE, 2023, 102 (33) : E34794
  • [42] LEAP-014: first-line lenvatinib plus pembrolizumab plus chemotherapy in advanced/metastatic esophageal squamous cell carcinoma
    Sun, Jong-Mu
    Adenis, Antoine
    C Enzinger, Peter
    Shah, Manish A.
    Kato, Ken
    Bennouna, Jaafar
    Doi, Toshihiko
    Hawk, Natalyn Nicole
    Yu, Li
    Shah, Sukrut
    Bhagia, Pooja
    Shen, Lin
    FUTURE ONCOLOGY, 2024,
  • [43] HEALTH OUTCOME IN PATIENTS WITH ADVANCED OR METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA TREATED WITH FIRST-LINE SINTILIMAB PLUS CISPLATIN AND PACLITAXEL VERSUS CISPLATIN AND PACLITAXEL
    Sun, L.
    VALUE IN HEALTH, 2022, 25 (12) : S53 - S53
  • [44] NEOADJUVANT CHEMOTHERAPY WITH ETOPOSIDE, LEUCOVORIN, 5-FLUOROURACIL AND CISPLATIN FOR ADVANCED ESOPHAGEAL SQUAMOUS-CELL CARCINOMA
    OHWADA, S
    NAKAMURA, S
    IZUMI, M
    KAWASHIMA, Y
    OGAWA, T
    KOBAYASHI, I
    HOSOMURA, Y
    JOSHITA, T
    LINO, Y
    MORISHITA, Y
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 1995, 25 (03) : 79 - 85
  • [45] Strategy Treatment of cT4b Esophageal Squamous Cell Carcinoma Using Docetaxel, Cisplatin, and 5-Fluorouracil
    NAKAJIMA, M. A. S. A. N. O. B. U.
    MUROI, H. I. R. O. T. O.
    KIKUCHI, M. A. I. K. O.
    KUBO, T. S. U. K. A. S. A.
    TAKISE, S. H. U. H. E. I.
    IHARA, K. E. I. S. U. K. E.
    NAKAGAWA, M. A. S. A. T. O. S. H., I
    MORITA, S. H. I. N. J. I.
    NAKAMURA, T. A. K. A. T. O. S. H., I
    YAMAGUCHI, S. A. T. O. R. U.
    KOJIMA, K. A. Z. U. Y. U. K. I.
    ANTICANCER RESEARCH, 2022, 42 (07) : 3725 - 3733
  • [46] DOCETAXEL PLUS CISPLATIN AS FIRST-LINE CHEMOTHERAPY IN PATIENTS WITH RECURRENT OR METASTATIC HEAD AND NECK CANCER
    Ohhara, Y.
    Nishimura, N.
    Nara, E.
    Nakano, K.
    Ueda, K.
    Sakajiri, S.
    Mishima, Y.
    Yokoyama, M.
    Terui, Y.
    Takahashi, S.
    Hatake, K.
    ANNALS OF ONCOLOGY, 2012, 23 : 125 - 125
  • [47] Efficacy and safety of KN046 plus paclitaxel/cisplatin as first-line treatment for unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).
    Xu, Jianming
    Liu, Rongrui
    Zhang, Yanqiao
    Xu, Nong
    Fan, Qingxia
    Gao, Shegan
    Pan, Hongming
    Cai, Mingquan
    Yan, Dong
    Liang, Qianqian
    Wu, Qiong
    Guo, Baohong
    Qi, Yakun
    Xu, Ting
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [48] First-line programmed cell death 1 inhibitor plus chemotherapy vs. standard treatment in patients with recurrent or metastatic oral squamous cell carcinoma: A retrospective cohort study
    Cheng, Lei
    Chai, Congna
    Liu, Yingqi
    Jiao, Jianjun
    ONCOLOGY LETTERS, 2024, 28 (02)
  • [49] Combination treatment of paclitaxel, cisplatin and infusional 5-fluorouracil (PCF) as first-line chemotherapy for metastatic or recurrent gastric cancer: Prospective multicenter clinical trial
    Jin, M.
    Zhang, X. D.
    Shu, Y. Q.
    Liang, J.
    Yang, J. W.
    Chen, L.
    Cao, W. G.
    Shi, G. M.
    Guo, C. Y.
    Zhang, F. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [50] Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-Line Treatment for Chinese Patients with Advanced Esophageal Squamous Cell Carcinoma: A Cost-Effectiveness Analysis
    Lu, Shijie
    Lou, Yake
    Rong, Yi
    Huang, Zirui
    Lin, Xiaodan
    Chen, Junying
    Luo, Kongjia
    CLINICAL DRUG INVESTIGATION, 2023, 43 (08) : 643 - 652
12345